Final results from Covidien's DEFINITIVE LE study, originally closed in 2012, finally appear in the Journal of American College of Cardiology, Cardiovascular Interventions.
It may have taken 2 years but final results from Covidien's (NYSE:COV) DEFINITIVE LE study finally appeared in the Journal of the American College of Cardiology's Cardiovascular Interventions issue.
Here's a look at some of the top regulatory stories for medical device companies this week: Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal; Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; Medtronic founder Bakken backs Covidien buy; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Allergan CFO Edwards steps down amid hostile Valeant takeover bid
, Biolase Technology Inc.
, Insulet Corp.
, Monarch Medical
, Pershing Square Capital Management
, Trinity Medical
, Valeant Pharmaceuticals
, Volpara Solutions
, Allergan Inc.
Medtech titans Medtronic and Covidien name more than 45 people to coordinate the finer points of their merger.
Here's a look at some of the top legal news stories for medical device companies this week: Another Covidien shareholder sues to block Medtronic merger; Ex-Integra sales rep, manager cop to $800k hospital fraud scheme; Diabetes: Medtronic, Johnson & Johnson settle patent spat; Stryker settles hip implant suit against J&J's DePuy; Appeals court reverses Medtronic's win in Lenox bone mill spat
Wright Medical Group Inc.
, Zimmer Holdings
, DePuy Synthes
, Integra LifeSciences Corp.
, Johnson & Johnson
, Lenox MacLaren Surgical Corp.
, Smith & Nephew
, Stryker Corp.
Medtronic CEO Omar Ishrak seeks to reassure employees amid the political fallout over the tax inversion aspects of its $43 billion deal to acquire Covidien.
Bearish options trades on Covidien are driven by speculation that Medtronic will follow Walgreen in abandoning plans for a so-called tax inversion deal, Bloomberg reports.
Earl Bakken, the founder of Medtronic, tells employees he's behind the company's $43 billion acquisition of Covidien and its potential to save a life every second.